HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TNF-derived peptides inhibit tumour growth and metastasis through cytolytic effects on tumour lymphatics.

Abstract
Tumour necrosis factor (TNF) is a multi-functional cytokine with profound and diverse effects on physiology and pathology. Identifying the molecular determinants underlying the functions and pathogenic effects of TNF is key to understanding its mechanisms of action and identifying new therapeutic opportunities based on this important molecule. Previously, we showed that some evolutionarily conserved peptides derived from TNF could induce cell death (e.g. apoptosis and/or necrosis), a feature of immune defence mechanisms shared by many vertebrates. In this study, we demonstrated that necrosis-inducing peptide P16 kills human glioblastoma cancer cells and primary human hepatoma or renal cancer cells isolated from patients who had not responded to standard treatments. Importantly, we show that the necrosis-inducing peptide P1516 significantly improves survival by inhibiting tumour metastasis in a 4T1 breast cancer syngeneic graft mouse model. Because the lymphatic system is an important metastatic route in many cancers, we also tested the effect of TNF-derived peptides on monolayers of primary human lymphatic endothelial cells (hDLEC) and found that they increased junctional permeability by inducing cytoskeletal reorganization, gap junction formation and cell death. Transmission electron microscopy imaging evidence, structural analysis and in-vitro liposome leakage experiments strongly suggest that this killing is due to the cytolytic nature of these peptides. P1516 provides another example of a pro-cytotoxic TNF peptide that probably functions as a cryptic necrotic factor released by TNF degradation. Its ability to inhibit tumour metastasis and improve survival may form the basis of a novel approach to cancer therapy.
AuthorsW Lu, Y Wang, Q Zhang, S Owen, M Green, T Ni, M Edwards, Y Li, L Zhang, A Harris, J-L Li, D G Jackson, S Jiang
JournalClinical and experimental immunology (Clin Exp Immunol) Vol. 198 Issue 2 Pg. 198-211 (11 2019) ISSN: 1365-2249 [Electronic] England
PMID31206614 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2019 British Society for Immunology.
Chemical References
  • Cytotoxins
  • Peptides
  • Tumor Necrosis Factor-alpha
Topics
  • Cytotoxins (chemistry, pharmacology)
  • Endothelial Cells (immunology, pathology)
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Jurkat Cells
  • Neoplasm Metastasis
  • Neoplasms (drug therapy, immunology, pathology)
  • Peptides (chemistry, pharmacology)
  • Tumor Necrosis Factor-alpha (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: